You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

IBRU

Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)      Intent: Palliative
Regimen Category: Evidence-Informed
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.

You might also be interested in